



Attorney Docket No. PC11088A
Application No. 09/995,130

1617

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, Washington, D.C. 20231 on this 4th day of April 2003.

By

Mary C. Bickel

(Signature of person mailing)

Mary C. Bickel

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): David B. MacLean, et al.

Examiner: Mojdeh Bahar

Application No.: 09/995,130

Art Unit: 1617

Filing Date: 11/27/2001

Title: THERAPY FOR ANDROPAUSE USING ESTROGEN AGONISTS/ANTAGONISTS AND TESTOSTERONE

Box Non-Fee Amendment
Commissioner for Patents
Washington, D.C. 20231

Sir:

RESPONSE

This is a response to the Official Action dated March 25, 2003, which contained only restriction and election of species requirements.

Remarks

Applicants have been required to elect a group of claims for prosecution from groups I-XII. Applicants hereby elect the claims of Group I, claims 1-10 and 31-45. Applicants have also been required to elect a species relating to a medical condition and a chemical species. Applicants hereby elect the medical condition andropause. In addition, applicants elect the chemical species disclosed in claim 4, which is (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalenen-2-ol. The claims that read on the elected chemical species and the elected medical condition are claims 1-5.

Applicants believe that this application is in condition for allowance. Reconsideration and allowance is respectfully requested.

Date:

4/4/2003

By:

Todd M. Crissey

Todd M. Crissey
Registration No. 37,807
Pfizer Inc
Patent Department,
Box 8260-1611
Eastern Point Road
Groton, CT 06340
Phone: (860) 715-4331
Fax: (860) 441-5221

TECH CENTER 1600/2900

APR 10 2003

RECEIVED